Bristol Myers Squibb (CELG-RI) Other Non-Current Assets (2009 - 2026)

Bristol Myers Squibb (CELG-RI) has reported Other Non-Current Assets for 18 consecutive years, with $6.4 billion the latest figure, recorded in Q2 2026.

• In Q2 2026, Other Non-Current Assets rose 7.45% year-over-year to $6.4 billion; the TTM figure through Jun 2026 stood at $6.4 billion (up 7.45% YoY), while the FY2025 annual figure was $6.5 billion, up 6.04% from the prior year.
• Other Non-Current Assets grew to $6.4 billion in Q2 2026 per CELG-RI's latest filing, from $6.1 billion in the prior quarter.
• Across five years, Other Non-Current Assets topped out at $6.5 billion in Q4 2025 and bottomed at $53.0 million in Q1 2023.
• Historically, Other Non-Current Assets has averaged $4.0 billion across 5 years, with a median of $5.9 billion in 2025.
• Annual changes were most pronounced in 2022 — Other Non-Current Assets sank 97.06% — and 2024, when it soared 11354.72%.
• Bristol Myers Squibb's Other Non-Current Assets stood at $4.9 billion in 2022, then climbed by 8.7% to $5.4 billion in 2023, then gained by 13.69% to $6.1 billion in 2024, then climbed by 6.04% to $6.5 billion in 2025, then declined by 1.48% to $6.4 billion in 2026.
• Business Quant data shows CELG-RI's Other Non-Current Assets at $6.4 billion in Q2 2026, $6.1 billion in Q1 2026, and $6.5 billion in Q4 2025.